SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

SCHEDULE 13G*

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED

IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c), AND

(d) AND AMENDMENTS THERETO

FILED PURSUANT TO RULE 13d-2

(AMENDMENT NO. )*

 

Eagle Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

269796-10-8

(CUSIP Number)

 

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

☒ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

13 G

CUSIP NO. 269796-10-8

Page 2 of 9 Pages

1

NAMES OF REPORTING PERSONS

 

Citigroup Global Markets Inc.

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)☐

 

(b)☐

3

SEC USE ONLY

 

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

New York

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5

SOLE VOTING POWER

 

 

 

6

SHARED VOTING POWER

 

1,000,000

 

 

7

SOLE DISPOSITIVE POWER

 

 

 

 

8

SHARED DISPOSITIVE POWER

 

1,000,000

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,000,000

 

 

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.7%

 

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

BD

 

 

.

 

 

 

 

13 G

CUSIP NO. 269796-10-8

Page 3 of 9 Pages

1

NAMES OF REPORTING PERSONS

 

Citigroup Financial Products Inc.

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)☐

 

(b)☐

3

SEC USE ONLY

 

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5

SOLE VOTING POWER

 

 

 

6

SHARED VOTING POWER

 

1,000,036

 

 

7

SOLE DISPOSITIVE POWER

 

 

 

 

8

SHARED DISPOSITIVE POWER

 

1,000,036

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,000,036

 

 

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.7%

 

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

CO

 

 

 

 

 

 

13 G

CUSIP NO. 269796-10-8

Page 4 of 9 Pages

1

NAMES OF REPORTING PERSONS

 

Citigroup Global Markets Holdings Inc.

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)☐

 

(b)☐

3

SEC USE ONLY

 

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

New York

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5

SOLE VOTING POWER

 

 

 

6

SHARED VOTING POWER

 

1,000,036

 

 

7

SOLE DISPOSITIVE POWER

 

 

 

 

8

SHARED DISPOSITIVE POWER

 

1,000,036

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,000,036

 

 

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.7%

 

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

HC

 

 

 

 

 

 

13 G

CUSIP NO. 269796-10-8

Page 5 of 9 Pages

 

1

NAMES OF REPORTING PERSONS

 

Citigroup Inc.

 

 

2

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

 

(a)☐

 

(b)☐

3

SEC USE ONLY

 

 

 

4

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

 

 

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

5

SOLE VOTING POWER

 

 

 

6

SHARED VOTING POWER

 

1,000,036*

 

 

 

7

SOLE DISPOSITIVE POWER

 

 

 

 

8

SHARED DISPOSITIVE POWER

 

1,000,036*

 

 

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

1,000,036*

 

 

 

10

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

 

☐

 

 

11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

7.7 %*

 

 

12

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

 

HC

 

 

* Includes shares held by the other reporting persons.

.

 

 

 

 

Item 1(a).

Name of Issuer:

 

Eagle Pharmaceuticals, Inc.

 

Item 1(b).

Address of Issuer's Principal Executive Offices:

 

50 Tice Boulevard, Suite 315

Woodcliff Lakes, NJ 07677

 

Item 2(a).

Name of Person Filing:

 

Citigroup Global Markets Inc. ("CGM")

Citigroup Financial Products Inc. ("CFP")

Citigroup Global Markets Holdings Inc. ("CGM Holdings")

Citigroup Inc. ("Citigroup")

Item 2(b).

Address of Principal Business Office or, if none, Residence:

 

The address of the principal business office of each of CGM, CFP, CGM Holdings and Citigroup is:

 

388 Greenwich Street

New York, NY 10013

 

Item 2(c).

Citizenship:

 

CGM and CGM Holdings are New York corporations.

 

CFP and Citigroup are Delaware corporations.

 

Item 2(d).

Title of Class of Securities:

 

Common Stock

Item 2(e).

CUSIP Number:

 

269796-10-8

 

 

 

Page 6

of 9 Pages

 

 

 

Item 3.

If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or

240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

 

 

(a)

☒ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

 

 

(b)

☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

 

 

(c)

☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

 

 

(d)

☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

 

 

(e)

☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);

 

 

(f)

☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);

 

 

(g)

☒ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);

 

 

(h)

☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

 

 

(i)

☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

 

 

(j)

☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);

 

 

(k)

☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .

 

Item 4.

Ownership. (as of November 11, 2024)

 

 

(a)

Amount beneficially owned: See item 9 of cover pages

 

 

(b)

Percent of class: See item 11 of cover pages

 

 

(c)

Number of shares as to which the person has:

 

 

(i)

Sole power to vote or to direct the vote:

 

 

(ii)

Shared power to vote or to direct the vote:

 

(iii)

Sole power to dispose or to direct the disposition of:

 

(iv)

Shared power to dispose or to direct the disposition of:

See Items 5-8 of cover pages

 

 

Page 7

of 9 Pages

 

 

 

Item 5.

Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

 

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

CFP is the sole stockholder of CGM. CGM Holdings is the sole stockholder of CFP. Citigroup is the sole stockholder of CGM Holdings.

Item 8.

Identification and Classification of Members of the Group.

 

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

 

Not Applicable.

 

 

Page 8

of 9 Pages

 

 

 

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE.

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: November 12, 2024

CITIGROUP GLOBAL MARKETS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP FINANCIAL PRODUCTS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

 

Page 9

of 9 Pages

 

EXHIBIT INDEX TO SCHEDULE 13G

 

EXHIBIT 1

Agreement among CGM, CFP, CGM Holdings and Citigroup as to joint filing of Schedule 13G.

 

 

 

EXHIBIT 1

AGREEMENT AS TO JOINT FILING OF SCHEDULE 13G

Each of the undersigned hereby affirms that it is individually eligible to use Schedule 13G, and agrees that this Schedule 13G is filed on its behalf.

Dated: November 12, 2024

CITIGROUP GLOBAL MARKETS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP FINANCIAL PRODUCTS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP GLOBAL MARKETS HOLDINGS INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

CITIGROUP INC.

 

By:

/s/ Ronny Ostrow

Name:

Ronny Ostrow

Title:

Assistant Secretary

 

 

Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Eagle Pharmaceuticals.